STOCK TITAN

Ginkgo Bioworks Holdings Inc - DNA STOCK NEWS

Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.

Overview

Ginkgo Bioworks Holdings Inc (NYSE: DNA) stands as a pioneering platform in cell programming, expertly harnessing synthetic biology and biosecurity to engineer new organisms designed to solve complex challenges across diverse industries. With a robust in-house pipeline that spans the design, build, and test phases, Ginkgo leverages state-of-the-art biological engineering techniques to deliver end-to-end solutions for sectors as varied as pharmaceuticals, food and agriculture, industrial chemicals, and specialty chemicals.

Business Model and Core Segments

Ginkgo organizes its operations into two primary business segments: Cell Engineering and Biosecurity. The Cell Engineering segment provides comprehensive R&D services, offering clients custom development of engineered organisms for improved process efficiency and product innovation. Meanwhile, the Biosecurity segment addresses the growing need for biological threat mitigation, delivering services that include monitoring, detection, and rapid response to safeguard public health and industrial operations. This bifurcated approach enables Ginkgo to generate revenue through contract-based services, strategic partnerships, and licensing agreements, thereby establishing a versatile platform for a wide array of customers.

Industry Impact and Technological Innovation

At the core of Ginkgo’s operations is a commitment to transforming biology through technological innovation. The company integrates advanced automation, high-throughput screening, and data analytics to accelerate the engineering of biological systems. Their proprietary cell programming platform, augmented by AI-driven tools such as protein language models and model APIs, empowers researchers in drug discovery and bioprocess optimization. By streamlining complex workflows, Ginkgo not only reduces the cost and time required for R&D but also fosters a new era of scalable, digitalized biology research.

Comprehensive Services and Strategic Partnerships

Ginkgo Bioworks distinguishes itself by offering a full spectrum of services—from engineering novel enzymes and proteins to developing robust biological data platforms that underpin modern AI applications. The company has forged strategic partnerships with prominent industry players, including collaborations with technology giants and renowned pharmaceutical companies, which reinforce its reputation as an integrative innovator. Such alliances enable Ginkgo to expand its research capabilities and bring advanced bioengineering solutions to markets ranging from agricultural feed additives to sophisticated healthcare diagnostics.

Competitive Positioning and Market Differentiation

In a competitive biotechnology landscape, Ginkgo’s comprehensive suite of services and its ability to couple biological expertise with cutting-edge technology provide a significant edge. Their approach combines academic rigor, deep domain expertise, and practical application of synthetic biology, setting them apart from companies that focus on single facets of the biotechnological chain. Key differentiators include:

  • End-to-End Solutions: From organism design to scale-up manufacturing, providing seamless integration across multiple stages.
  • Advanced Automation: Utilization of high-throughput systems and custom automation services that significantly enhance research productivity.
  • AI Integration: Deployment of machine learning models and data-as-a-service offerings that optimize biological research and operational efficiency.
  • Robust Research and Development: Continuous investment in innovative R&D to both refine existing processes and develop transformative bioengineering technologies.

This integrated approach not only bolsters their technical prowess but also instills confidence in their ability to manage complex challenges in cell programming and biosecurity. Their interdisciplinary teams, which merge the insights of biology, chemistry, engineering, and computer science, ensure that they remain at the forefront of technological advancements and industry trends.

Conclusion

Ginkgo Bioworks exemplifies a modern biotechnology firm that leverages the power of synthetic biology and automation to unlock new frontiers in industrial and healthcare applications. Its dual-segment strategy, combining Cell Engineering and Biosecurity, coupled with significant advancements in AI and high-throughput data generation, positions the company as a formidable force in the biotech landscape. By offering comprehensive, scalable, and innovative bioengineering solutions, Ginkgo continues to enable transformative progress across a host of industries, solidifying its reputation as a trusted partner for organizations intent on redefining how biology is engineered to meet the world’s most challenging needs.

Rhea-AI Summary

Clinical Enterprise, a Eurofins Scientific Company, has partnered with Ginkgo Bioworks (NYSE: DNA) to expand Operation Expanded Testing, which provides no-cost COVID-19 PCR testing to schools, community organizations, and underserved populations. This initiative, funded by the U.S. Government, supports K-12 schools, correctional facilities, and other settings to reduce transmission of the virus. Ginkgo's Concentric program facilitates testing for over 220,000 individuals weekly, aiming to promote public health equity and prevent outbreaks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
partnership covid-19
-
Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) confirmed the detection of the Omicron variant in pooled samples from air travelers arriving at Newark International Airport. This detection was part of a COVID-19 monitoring program developed in partnership with the CDC and XpresSpa Group (Nasdaq: XSPA). The program utilizes Concentric's testing infrastructure and XpresCheck's in-airport testing. Currently operational in four major airports, the initiative aims to enhance biosecurity and provide rapid public health responses. Ginkgo's Concentric has expanded its testing capabilities significantly, serving tens of millions weekly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
covid-19
-
Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) announced its participation in several upcoming conferences aimed at showcasing its cell programming platform. The events include the Piper Sandler Annual Healthcare Conference on November 30, 2021, the Jefferies Alternative Protein & Related ESG Summit on December 1, 2021, and the Goldman Sachs Byte-ology Conference on December 9, 2021. More details, including webcast links and replays, will be available on their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences
Rhea-AI Summary

On November 17, 2021, mRNA Victoria and Ginkgo Bioworks (NYSE: DNA) announced a strategic partnership aimed at enhancing vaccine development and biosecurity initiatives in Australia. Ginkgo will establish an office in Melbourne, signifying potential long-term growth in the Australian biotech sector. This collaboration leverages Ginkgo's cell programming capabilities, which have contributed to advancements in diagnostics and vaccine manufacturing, as well as other sectors like food and agriculture. Ginkgo aims to expand its operations in Australia, contributing to the local biotechnology ecosystem.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
partnership
-
Rhea-AI Summary

Ginkgo Bioworks, listed under ticker DNA, reported a strong third quarter for 2021 with total revenue reaching $77.6 million, up from $13.3 million in the previous year. Year-to-date revenue stands at $165.3 million, a 271% increase. Foundry revenue rose 202% to $34.7 million, while biosecurity revenue reached $42.9 million with a 48% gross margin. Despite a loss from operations of $26.7 million, cash reserves are strong at $1.7 billion. Ginkgo has exceeded its outlook for biosecurity revenue, now expecting at least $110 million for the full year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) has launched its Cell Development Kits (CDKs) service, aimed at simplifying access for aspiring cell developers to program cells for various applications. The initial focus is on protein expression programs, providing essential tools for commercial protein development, starting at $100,000. This service is designed to reduce costs and accelerate timelines, allowing customers to prototype ideas in phases. CEO Jason Kelly emphasized the potential of engineered biology to drive innovation across multiple industries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
Rhea-AI Summary

Synlogic (SYBX) and Ginkgo Bioworks (DNA) announced the nomination of SYNB1353, an investigational Synthetic Biotic medicine for homocystinuria (HCU). This marks the first product from their collaboration and the first developed on Ginkgo's platform to enter IND-enabling studies. Synlogic aims to file an IND application for SYNB1353 with the FDA in 2022. SYNB1353 is designed to lower plasma homocysteine by metabolizing methionine in the GI tract, providing new treatment options for patients with HCU, a disorder with limited existing therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) is set to host a presentation on November 15, 2021, at 8:00 a.m. ET to discuss its third-quarter business performance for the period ending September 30, 2021. Investors can find presentation details and registration on Ginkgo's investor relations website, where a replay will also be available. Questions can be submitted beforehand via Twitter or email. Ginkgo is advancing biotechnology applications in sectors like food, agriculture, and pharmaceuticals, contributing to COVID-19 response efforts such as pooled testing and vaccine optimization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.95%
Tags
none
-
Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) hosted its annual conference, Ferment, on October 28, 2021, gathering key stakeholders from the synthetic biology ecosystem. The event featured presentations on various topics, including biosecurity, advancements in cell therapies, and the future of synthetic biology. Notable discussions included a keynote from co-founder and CEO Jason Kelly and insights from industry leaders like Arie Belldegrun and Scott Gottlieb. Following the event, videos and additional information will be available on Ginkgo's investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
Rhea-AI Summary

On October 27, 2021, Arcaea, a company launched on the Ginkgo Bioworks platform, announced a $78 million Series A funding round aimed at revolutionizing the beauty industry through innovative biological products. The funding from notable investors like CHANEL and Viking Global will enable Arcaea to develop sustainable beauty ingredients using DNA sequencing and biological engineering. CEO Jasmina Aganovic emphasized the potential of biology as a tool for creative self-expression and sustainability in beauty, aiming to create a new supply chain that avoids petrochemicals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none

FAQ

What is the current stock price of Ginkgo Bioworks Holdings (DNA)?

The current stock price of Ginkgo Bioworks Holdings (DNA) is $5.66 as of April 1, 2025.

What is the market cap of Ginkgo Bioworks Holdings (DNA)?

The market cap of Ginkgo Bioworks Holdings (DNA) is approximately 324.4M.

What is the core business of Ginkgo Bioworks?

Ginkgo Bioworks operates as a platform for cell programming, using synthetic biology to engineer organisms that address challenges across diverse industries.

Which key segments does Ginkgo organize its operations into?

The company is structured around two primary segments: Cell Engineering, which offers custom biological R&D services, and Biosecurity, which focuses on monitoring and mitigating biological threats.

How does Ginkgo Bioworks generate revenue?

Revenue is derived from a combination of contract-based R&D services, strategic partnerships, and licensing arrangements, all focused on enhancing biological processes and biosecurity solutions.

What industries benefit from Ginkgo's services?

Their end-to-end bioengineering solutions serve a broad array of industries including pharmaceuticals, food and agriculture, industrial chemicals, and specialty chemicals.

How does Ginkgo incorporate advanced technology into its offerings?

The company integrates automation, high-throughput screening, and AI-driven tools such as protein language models and data platforms to streamline biological research and accelerate innovation.

How is Ginkgo differentiated from its competitors?

Ginkgo stands out by combining comprehensive R&D services with a strong emphasis on automation and AI integration, supported by strategic partnerships and interdisciplinary expertise.

Can you elaborate on Ginkgo's approach to synthetic biology?

Ginkgo utilizes an in-house pipeline for designing, building, and testing new organisms, enabling them to tailor cell-based solutions that meet the specific needs of various markets.

Who are the typical clients of Ginkgo Bioworks?

Their clients range from government agencies requiring biosecurity solutions to biotech and pharmaceutical companies, as well as organizations in agriculture and industrial sectors seeking innovative biological engineering services.
Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Stock Data

324.41M
54.25M
6.6%
79.85%
15.62%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON